During the trial, participants receive the infusion of the study drugs in a medical setting and are then monitored for side effects, changes in lab tests, vital signs, and heart rhythm measured by an ECG. Researchers also look for signs that the cancer is responding, using a set of rules called RECIST to measure tumor size on scans. Outcomes such as the proportion of patients whose tumors shrink (ORR), the proportion whose disease stops growing (DCR), how long any shrinkage lasts (DoR), and the time before the cancer gets worse (PFS) are recorded. In addition, a laboratory technique known as qPCR is used to track the engineered cells in the blood. The study follows participants for several months after treatment to gather this information.

The purpose of the study is to assess how safe the investigational drug is and to determine the appropriate dose when used alone or in combination with the hormone therapies.

Participants will first undergo screening tests, then begin taking the study medication in a series of visits. Depending on the study arm, they may receive an injection of the hormone blocker, a daily pill, or both, alongside the oral investigational drug. Throughout the study they will have regular check‑ups that include blood work, vital‑sign measurements, and heart rhythm checks to monitor safety. Treatment continues until the cancer shows growth, side effects become unacceptable, or the study ends.

The main purpose is to see how many participants can go at least 12 weeks without their disease getting worse. After an initial screening, participants receive the infusion every few weeks and are checked regularly with scans and blood tests. Changes in tumor size are measured using standard criteria (RECIST) to determine if the cancer is shrinking, staying the same, or growing. Safety is monitored by asking about side effects and using questionnaires that assess quality of life throughout the study.

The study follows people who receive the study drug and looks at how the treatment is tolerated over time. Some extra testing of tumor samples or blood samples may be done to look for markers in the cancer, which are small signs that can help explain how the cancer is behaving. These tests are optional and are used for research only.

The research aims to determine the best dose of the study drugs and how well the combination works in different types of cancer. Participants will receive these medications as part of a structured process to monitor how the body reacts to the treatment. During the study, the focus is on observing how the drugs are tolerated and tracking any side effects that may occur.

The purpose of the study is to find out if EP0031 is safe and how well it works in treating cancers with RET changes. The study is divided into different parts called modules. Module A will look at the safety of EP0031 and help determine the right dose to use. Modules B and C will test how well EP0031 works at shrinking tumors and will continue to monitor safety. The study will measure how tumors respond to treatment, how long the response lasts, and how long people live without their cancer getting worse. For some people in the study, tissue samples from their tumor may be taken before and during treatment to better understand how the medicine works.

During the study, people will take EP0031 regularly and visit the study site for check-ups. These visits will include physical examinations, blood tests, heart monitoring with an ECG, and scans to see how the cancer is responding to treatment. The study doctors will watch for any side effects and measure the amount of medicine in the blood to understand how the body processes it. Different groups of people will be placed into different cohorts based on their type of cancer, whether they have received previous RET-targeted treatment, and other factors. The study will continue until enough information is gathered about the safety and effectiveness of EP0031 in treating these types of cancer.

The purpose of this study is to find out if BAY 3713372 is safe, how it affects the body, what side effects it may cause, and whether it can help treat these types of tumors. The study will also determine the right dose of this medicine to use, both when given alone and when combined with other cancer treatments. Additionally, researchers want to understand how the medicine moves through the body and how it may affect tumor growth.

The study will happen in two main parts. In the first part, called dose escalation, different doses of BAY 3713372 will be tested in small groups of people to find a safe and effective dose. Participants will be closely monitored for any side effects, and blood samples will be taken to measure the levels of the medicine in the body. In the second part, called dose expansion, a larger number of people with specific types of MTAP-deleted tumors will receive the selected dose of BAY 3713372, either alone or combined with other cancer treatments. Throughout the study, participants will have regular check-ups, scans to measure their tumors, and blood tests. The treatment is given in cycles, with each cycle lasting 21 days, and participants may continue treatment as long as it is helping them and not causing unacceptable side effects.

The study involves giving the two medicines directly into the tumor over a period of up to six weeks before the planned surgery. During this time, patients will receive nivolumab at a dose of up to 30 milligrams per day with a total of up to 90 milligrams, and ipilimumab at a dose of up to 25 milligrams per day with a total of up to 75 milligrams. After completing the treatment, patients will undergo surgery to remove the tumor. The doctors will then examine the removed tissue to see how much of the cancer was destroyed by the treatment. The study will measure whether the cancer was completely eliminated or whether there was a major response with less than 10 percent of cancer cells remaining.

Throughout the study, doctors will monitor patients for any side effects and will check whether the treatment causes any delays in the planned surgery date. After surgery, patients will be followed to see how long they remain free of cancer and to track their overall health and survival. The study will also assess quality of life using questionnaires at different time points during and after treatment. Safety will be monitored by tracking all side effects according to standard cancer treatment safety guidelines. The study will continue to follow patients for several years after surgery to see if the cancer returns and to measure long-term outcomes.

The study consists of two parts. The first phase aims to find the right dose of the medications and assess their safety. The second phase focuses on determining how well the treatments work in fighting the cancer. The types of cancer being studied include non-small cell lung cancer, biliary tract cancer, pancreatic cancer, gastroesophageal cancer, and glioblastoma (a type of brain tumor), as long as they have the specific MTAP genetic characteristic.

During the study, participants will receive either S095035 alone or in combination with TNG462. The researchers will monitor how the medications affect the tumors and track any side effects that may occur. They will also study how the medications are processed by the body and measure various aspects of the treatment’s effectiveness, such as how long it takes for tumors to respond and how long the response lasts.

The medications being studied include S-241656, which is taken as an oral tablet, and several other drugs administered through an intravenous method, which means they are delivered directly into a vein. These other medications include oxaliplatin, cetuximab, panitumumab, gemcitabine, paclitaxel, irinotecan, fluorouracil, and folinic acid. During the study, different doses of these treatments may be used to determine the most appropriate amount for patients.

The study is divided into two main stages. In the first stage, the focus is on finding the safest dose of the medication. In the second stage, the study looks at how well the treatment works to shrink or control the cancer. Throughout the process, the way the body processes the medicine is also observed.

In the first part of the trial, small groups of participants will receive increasing amounts of the drug given by an intravenous infusion (a medicine delivered directly into a vein) to determine how the body tolerates it and to find the dose that seems most promising. Once a recommended dose is set, the second part continues with more participants receiving that dose, while doctors watch for side effects and check how the tumors respond. Tumor changes are measured using a standard method called RECIST v1.1, which compares scans taken before and after treatment to see if the cancer gets smaller, stays the same, or grows.

Throughout the study, participants will have regular medical visits, blood tests, and imaging scans to monitor safety and any signs that the tumor is responding. Researchers will record any adverse events, track how long any tumor shrinkage lasts, and note how long participants remain free from disease progression. The overall goal is to gather information that could lead to larger studies and eventually new treatment options for people with advanced solid tumors.

During the study, participants will receive treatments through an intravenous infusion, which is a method where medicine is delivered directly into a vein. The process involves monitoring how the body handles the drugs and observing how the tumors respond to the combined treatment. This research is divided into different stages to first determine the safest dose of the medication and then to measure how much the cancer shrinks or how long it stays under control.

The trial will observe how the body responds to DS-3790A when it is used alone or in combination with other medicines. The course of the study involves administering these medications through an infusion, which is a method of delivering fluids or medicine directly into a vein. Researchers will monitor for any side effects or changes in the disease to understand how well the treatment works.

The treatment, TAX2, is administered through an intravenous infusion, which is a method of delivering medicine directly into a vein using a tube. The purpose of the study is to determine how much of this drug can be safely given and how it behaves within the body. During the initial part of the study, different amounts of the medicine are given to patients to find the most appropriate dose. This is followed by a phase where a specific amount is tested in a larger group to continue monitoring safety and how the drug affects the tumor.

Researchers will monitor how the body processes the medicine, known as pharmacokinetics, and how the medicine affects the body’s biological functions, known as pharmacodynamics. Scientists will also look for any adverse events, which are side effects or unintended medical problems that may occur during the treatment. The study aims to see if there is any anti-tumour activity, meaning the medicine has the ability to shrink or stop the growth of the cancer cells.

The purpose of the study is to evaluate the safety, tolerability, and how well IPN60300 works against tumours in adults who have received previous treatment that did not work or who have no other standard treatment options available. The study will also look at how the body processes the medication, how it affects the body, and whether the immune system develops a response to it. During the study, participants will receive IPN60300 in cycles that last 21 days each, and their health and tumour response will be monitored regularly through physical examinations, blood tests, and imaging scans to see if the tumours are shrinking, staying the same, or growing.

The study will track various outcomes including any side effects that occur, how many people respond to the treatment with their tumours shrinking or disappearing, and how long these responses last. Participants will be followed throughout their treatment and for a period after their last dose to ensure their safety and to gather complete information about how the medication works. The entire study is expected to last approximately three years, during which participants will have regular visits to assess their condition and response to treatment.

The study is divided into two parts. In the first part, called Phase 1, the researchers will test different doses of WEF-001 to find out which dose is safe and appropriate for further testing. They will closely watch for any side effects and measure how the medicine moves through the body. In the second part, called Phase 2a, the study will focus on one specific type of cancer from among pancreatic cancer, colorectal cancer, or non-small cell lung cancer, and will test whether WEF-001 can help shrink tumours at the dose chosen from Phase 1.

People taking part in the study must have already tried at least one standard treatment for their cancer that did not work or stopped working. During the study, participants will receive WEF-001 and will have regular check-ups that include blood tests, scans to measure tumours, and monitoring for any side effects. The study will continue to follow participants to see how long the treatment works and how it affects their overall health. Some participants may also have tissue samples taken from their tumour to help researchers learn more about how WEF-001 works.

The purpose of this study is to find out if ECI830 is safe when given alone or with other treatments, to determine the right dose to use, and to see if the combination of ECI830 with ribociclib and fulvestrant can help stop the cancer from getting worse in patients with HR-positive HER2-negative breast cancer who have already received treatment with a type of medicine called a CDK4/6 inhibitor. The study will also look at how well these treatments work against the cancer by measuring things like whether tumors shrink or stop growing.

The study has two parts. The first part will test different doses of ECI830 to see what side effects occur and to find the best dose to use. The second part will give the chosen dose of ECI830 in combination with ribociclib and fulvestrant to a larger group of patients with breast cancer to see how well this combination works. During the study, patients will have regular check-ups where doctors will monitor their health, take blood samples, check heart activity, and use imaging scans to see how the cancer is responding to treatment. The study will track how long patients live without their cancer getting worse and how long they survive overall.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

The purpose of this study is to find the best dose of selenium that can be given safely over 99 hours while producing the best results in treating the cancer. The study will test different doses to see which one gives the best response without causing serious side effects. Patients will receive sodium selenite through a continuous infusion that lasts for 99 hours, which is just over four days. During this time, blood and urine samples will be collected to measure how the body processes the selenium. After the selenium treatment is finished, patients will receive chemotherapy. Scans will be taken before and after the treatments to see if the tumors have responded.

The study will track several things including how well the tumors respond to the selenium treatment and to the chemotherapy that follows, whether patients experience improvement in their symptoms and overall health status, how selenium moves through the body and stays in the blood, and whether there are any side effects from the treatment. Patients participating in this study must have cancer that has continued to grow despite receiving all standard treatments that are normally used for their type of cancer. The study will continue to follow patients over time to see how long they survive after receiving the treatment.

The study is divided into different parts called cohorts, which are groups of participants. Some participants will receive DT-7012 alone to help determine the best dose, while others will receive it together with pembrolizumab. The medication will be given through intravenous infusion, which means it will be delivered directly into a vein through a needle. Throughout the study, doctors will monitor participants for any side effects or unwanted reactions to the treatment. They will also check how the medication moves through the body and how long it stays in the bloodstream.

In addition to safety monitoring, the study will evaluate whether the treatment has any effect on the cancer. This includes checking if tumors shrink, stay the same size, or stop growing for a period of time. The study will involve multiple visits where participants will undergo various tests and examinations to track their health and the response of their cancer to the treatment. This is an early phase study designed to gather important information about how DT-7012 works in people with advanced solid tumors.

The purpose of the study is to find out if TLN-372 is safe and how well it works against these types of cancers, both when given alone and when combined with other cancer medications. The study will look at what side effects occur, how the body processes the medication, and whether the tumors shrink or stop growing during treatment. The first part of the study will determine the appropriate dose of TLN-372 by carefully monitoring patients for any safety concerns. The second part will examine how effective the medication is at fighting cancer and will test different combinations of treatments.

During the trial, patients will receive TLN-372 either by itself or together with one of the other cancer medications. Doctors will regularly check how patients are responding to treatment through various tests and examinations. The study will monitor for any unwanted effects from the medications and will measure changes in the size of tumors over time. Blood tests will be performed to understand how the medication moves through the body and how long it stays in the system. The trial will continue until enough information is gathered about the safety and effectiveness of these treatment approaches.

During the study, people will receive MK-1084 as tablets. Some people will also receive cetuximab, which is given through a vein. The study will compare how well MK-1084 works by itself compared to when it is given together with cetuximab. The study will measure how many tumors respond to the treatment and whether they get smaller. It will also track how long the treatment keeps working and how long people live. Throughout the study, doctors will carefully watch for any side effects or unwanted reactions to the medications.

The study will look at different types of solid tumors that have the KRAS G12C mutation, but it will not include colorectal cancer. People joining the study will have already tried standard treatments for their cancer that did not work or stopped working. The study will continue for several years to gather information about how well the treatments work over time and to ensure the safety of people taking part in the research.

The main purpose of this research is to evaluate how well different doses of BMS-986504 work in treating this specific type of lung cancer. The medication will be given to patients whose cancer has continued to grow or spread despite previous treatments. This is an open-label study, which means both doctors and patients will know which treatment is being given.

During the study, patients will take the medication and have their cancer monitored regularly to see how it responds to the treatment. Doctors will track if the tumors shrink, stay the same size, or grow. They will also monitor how patients feel and any side effects they may experience. The study will look at various aspects of the treatment’s effectiveness, including how long the cancer stays controlled and how long patients survive after starting the treatment.

The purpose of this research is to understand how safe the medication is and how well patients tolerate it, while also examining its effectiveness against these types of cancer. The study is divided into two parts. In the first part, researchers will determine the safe dose of the medication. In the second part, they will focus on how well the treatment works in fighting the cancer.

During the study, participants will receive WEF-001 as a single treatment. The medication will be given in the form of a powder that is mixed with liquid and then administered through a vein. Participants will be monitored regularly to check their response to the treatment and any side effects that may occur. The study will include patients whose cancer has continued to grow after trying at least one standard treatment.

The study will be conducted in two parts. In the first part, the focus will be on finding the right dose of GSK5733584 when used with the other medications. This will help establish the recommended dose for future studies. In the second part, the study will evaluate how well the combination treatments work compared to using GSK5733584 alone. Participants will receive the treatments through an intravenous infusion, which means the medication will be given directly into a vein.

Throughout the study, researchers will monitor participants for any side effects and measure how the cancer responds to the treatment. The study aims to provide valuable information on the potential benefits of combining GSK5733584 with other anti-cancer drugs for people with advanced solid tumors. The study is expected to continue until 2028, with recruitment starting in 2025.

The purpose of this study is to evaluate how safe and effective the combination of PRT3789 and pembrolizumab is for patients with these specific types of cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor how patients respond to the treatment over time, looking at factors such as any side effects they experience and how well the treatment works in controlling the cancer.

Throughout the study, researchers will collect information on the safety of the treatment and how well it helps in reducing or controlling the cancer. This includes observing any changes in the size of the tumors and the overall health of the participants. The study aims to provide valuable insights into whether this combination of medications can offer a new treatment option for patients with these challenging types of cancer.

Participants in the study will receive the treatment through different methods, such as intravenous use, which involves administering the medication directly into a vein, or oral intake, which involves taking the medication by mouth. The study will monitor participants for any side effects and determine how the body processes the medication. The goal is to identify safe doses that can be tested in larger groups of patients in the future.

The trial will take place over several years, with an estimated end date in 2028. Throughout the study, researchers will collect data on the number of participants experiencing side effects, the concentration of the medication in the blood, and the overall response to the treatment. This information will help determine the potential benefits and risks of using BMS-986507 in treating advanced solid tumors and specific types of lung cancer.

The purpose of the study is to find the best dose of ETX-19477 that patients can tolerate and to understand how safe it is. The study will also look at how well the drug works against the cancer. The study is divided into two phases. In the first phase, researchers will determine the safest dose and observe any side effects. In the second phase, they will assess how effective the drug is in treating the cancer. Participants will take the medication by mouth and will be monitored regularly to check their health and the cancer’s response to the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their cancer. The study aims to provide valuable information about the potential benefits and risks of using ETX-19477 for treating advanced solid cancers. This research could lead to new treatment options for patients with these types of cancers in the future.

Participants in the study will receive colchicine, which is taken orally, to see if it can help manage the inflammation in their coronary arteries, which are the blood vessels that supply the heart. The study will also involve the use of a special type of scan called a PET-scan to measure changes in the blood vessels over a period of 12 weeks. This scan helps to visualize how much of a certain substance, called 68Gallium-DOTATATE, is taken up by the blood vessels, which indicates the level of inflammation.

The trial will also monitor other health indicators, such as the condition of the carotid arteries and aorta, which are major blood vessels, as well as the overall health of the spleen and bone marrow. Additionally, the study will track any major heart-related events, like heart attacks or strokes, and any side effects related to the immune therapy. The goal is to understand if colchicine can provide a protective effect for patients undergoing cancer treatment, potentially improving their overall health outcomes.

The purpose of this study is to find the best dose of GEN1078 that can be safely given to patients and to see how well it works against the tumors. The study will start by giving small doses of GEN1078 to participants and gradually increasing the dose to find the maximum amount that can be tolerated without causing severe side effects. This part of the study is called dose escalation. After finding the right dose, more participants will receive this dose to further evaluate its safety and how well it works in shrinking or controlling the tumors. This is known as the dose expansion phase.

Throughout the study, researchers will closely monitor participants for any side effects and measure how the tumors respond to the treatment. The study aims to gather important information about the treatment’s safety and its potential to help people with malignant solid tumors. The trial is expected to continue until 2027, providing valuable insights into the use of GEN1078 for treating these types of cancers.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The purpose of the study is to understand how well these drugs work against tumors and to monitor any serious side effects that may occur. Participants will take the medications orally, either as capsules or tablets, over a period of time. The study will track the progress of the disease and any changes in the patient’s condition. The trial will also look at how long patients can live without the cancer getting worse and their overall survival during the study period.

By repurposing these drugs, the study hopes to provide new treatment options for patients with limited choices. The trial will gather information on the safety and effectiveness of these medications in treating rare cancers, potentially leading to new ways to manage these challenging conditions.

Participants in the study will receive either the combination of D,L-methadone and mFOLFOX6 or mFOLFOX6 alone. The study will be conducted in two phases. The first phase will focus on understanding the safety and appropriate dosage of D,L-methadone when used with mFOLFOX6. The second phase will assess the effectiveness of the combination in controlling the cancer. Some participants may receive a placebo instead of D,L-methadone to compare the outcomes. The study will monitor the response of the cancer to the treatment over a period of 12 weeks.

The trial aims to provide insights into whether adding D,L-methadone to the standard mFOLFOX6 treatment can improve outcomes for patients with advanced colorectal cancer. The study will also look at the overall survival, quality of life, and safety of the treatment. Additionally, researchers will examine the expression of a specific protein called the μ opioid receptor in tumor tissue to see if it affects the treatment’s effectiveness. The study is expected to continue until October 2027.

Participants in the study will receive the imaging agent 89Zr-Df-crefmirlimab through an intravenous injection, which means it is delivered directly into the bloodstream. The study will involve several PET scans to monitor the distribution of the imaging agent in the body and its uptake by tumors. These scans will be conducted at different times to see how the imaging agent behaves before and during the cancer treatment. The study will also collect information on how the tumors change in size and appearance during the treatment using imaging techniques like MRI.

The purpose of this study is to gather information that could improve the understanding of how the immune system interacts with cancer during treatment. This could potentially lead to better ways to monitor and treat metastatic solid tumors in the future. The study will run over several years, with participants being monitored throughout their treatment to assess the effectiveness and safety of the imaging agent and the cancer therapy. The trial will also look at any side effects or reactions to the treatments used in the study.

The purpose of the study is to evaluate how well the 68Ga-ABS011 PET/CT works compared to the standard tests currently used to check the status of a protein called HER2 in breast cancer. During the study, participants will receive an injection of 68Ga-ABS011, and then undergo a PET/CT scan. This will help doctors determine if the new method provides better or additional information compared to the usual tests. The study will also monitor any side effects that participants might experience from the injection or the scan.

Participants in the study will have several visits over a period of time, during which they will undergo the PET/CT scan and possibly a biopsy, which is a procedure to take a small sample of tissue for testing. The study aims to see if the new imaging method can help guide treatment decisions and improve the management of metastatic breast cancer. The trial is expected to continue until the end of 2025.

The study is divided into two phases. In the first phase, the focus is on determining the best dose of JAB-21822 that can be given safely to patients. This phase will also look at how the body processes the medication. In the second phase, the study will further explore how well JAB-21822 works in shrinking tumors, both on its own and in combination with another drug called cetuximab for a specific type of cancer known as metastatic colorectal cancer with the same mutation.

Throughout the study, participants will receive regular check-ups to monitor their health and any side effects they may experience. The study will continue until the end of 2025, with the goal of gathering enough information to understand the potential benefits and risks of using JAB-21822 as a treatment option for these types of cancer.

The purpose of the study is to assess the safety and tolerability of ART6043 when used alone and in combination with other cancer medications, such as olaparib and niraparib. Olaparib and niraparib are known as PARP inhibitors, which are drugs that also interfere with the DNA repair process in cancer cells. The study will explore how well ART6043 works when combined with these PARP inhibitors, especially in patients with specific types of breast cancer that have certain genetic mutations, like the BRCA mutation.

Participants in the study will receive ART6043 either by itself or alongside olaparib or niraparib. The study will monitor the participants for any side effects and measure how the cancer responds to the treatment. The goal is to determine the best dose of ART6043 and to see if the combination treatments are more effective than the PARP inhibitors alone. The study will take place over several years, with regular check-ups and assessments to ensure the safety and effectiveness of the treatment.

The purpose of this study is to determine the most suitable dose and to establish the safety profile of GEN1046. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will start with a dose-escalation phase, where different doses of the medication are tested to find the safest and most effective dose. After this, there will be an expansion phase to further evaluate the treatment’s safety and effectiveness in a larger group of patients.

Throughout the study, researchers will monitor participants for any side effects and assess how well the treatment works against the tumors. The trial aims to provide valuable information on the potential benefits and risks of using GEN1046 in treating these types of cancer. The study is expected to continue until early 2026, allowing enough time to gather comprehensive data on the treatment’s safety and effectiveness.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

The purpose of this study is to evaluate the safety and effectiveness of these treatment combinations. The study is divided into two parts. In the first part, researchers aim to find the best dose of DuoBody®-CD40x4-1BB when used with radiotherapy, with or without pembrolizumab. In the second part, the study will assess how well these treatments work together in shrinking tumors that have not been directly treated with radiation. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, participants will be monitored for any side effects and how their cancer responds to the treatment. The study will also look at how long the treatment effects last and the overall survival of participants. This trial is expected to continue until December 2025, providing valuable information on the potential benefits of combining these therapies for treating metastatic solid tumors.